Last reviewed · How we verify
Terizidon (TERIZIDONE)
Terizidon (generic name: TERIZIDONE) is a terizidone drug. It is currently in Phase 2 development.
Terizidone works by inhibiting the activity of certain enzymes in the brain.
Terizidon is a small molecule used in the treatment of tuberculosis, including multidrug-resistant and extensively-drug resistant forms, as well as HIV infections. It is administered as part of individualized or standardized treatment regimens, often in combination with other drugs.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | TERIZIDONE |
|---|---|
| Drug class | terizidone |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Think of it like a key that unlocks a door. In this case, the key is terizidone, and the door is the brain's ability to make certain chemicals that can cause problems. By blocking these chemicals, terizidone can help reduce symptoms of certain conditions.
Approved indications
Common side effects
- Myelosuppression
- Drug resistance
- Polyneuropathy
- Electrocardiogram QT prolonged
- Anaemia
- Neuropathy peripheral
- Bicytopenia
- Treatment failure
- Psychotic disorder
Key clinical trials
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- The Individualized M(X) Drug-resistant TB Treatment Strategy Study (PHASE4)
- An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis (PHASE2,PHASE3)
- Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Terizidon CI brief — competitive landscape report
- Terizidon updates RSS · CI watch RSS
Frequently asked questions about Terizidon
What is Terizidon?
How does Terizidon work?
What is the generic name of Terizidon?
What drug class is Terizidon in?
What development phase is Terizidon in?
What are the side effects of Terizidon?
Related
- Drug class: All terizidone drugs
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing